Reversal of CTLA4Ig-mediated tolerance to cardiac allografts by exogenous interleukin-2.
Arima
T
T
Surgery Department, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Rehman
A
A
Flye
M W
MW
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D060908:CTLA-4 Antigen; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D018796:Immunoconjugates; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D011920:Rats, Inbred WF; D011994:Recombinant Proteins / Q000494:pharmacology; D013997:Time Factors; D014184:Transplantation, Homologous
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; D000069594:Abatacept